iCare for Cancer Patients is a precision oncology program with the mission of improving patient survival. By using a variety of new molecular biology tools and computational biology software, iCare clinicians and scientists are finding the right drugs for the right patients.
For patients, iCare tailors treatments based on the patient’s disease, rather than one-size-fits-all treatment. For referring physicians, iCare helps weigh treatment options and find new ones. For patient advocacy groups, iCare digitally screens for new drug or drug combinations to attack diseases of interest. For pharmaceutical companies, iCare screens for diseases that will respond to drugs of interest and defines gene signatures corresponding to drug sensitivity or resistance. This information helps build companion diagnostics and precision enrollment studies.
The iCare program works with:
- Patients and Caregivers
- Research Scientists
- Pharmaceutical Companies
- Patient Advocacy Organizations
For more information, please contact Christopher R. Cogle, M.D., at email@example.com or 1-352-273-7493.
Administrative contact: Kristen Frack Kristen.Frack@medicine.ufl.edu | 352-273-8699
|iCare 1||MDS, AML, MF, MM, ALL||Cogle||Feasibility and prospective validation study of computer-informed treatment|
|iCare 2||Relapsed and refractory MDS||Cogle||Randomized controlled trial of computer-informed vs. conventional care|
|iCare 3||AML||Drusbosky||Feasibility and prospective validation study of ddPCR monitoring of MRD|
|iCare 4||Relapsed and refractory AML||Norkin||Midostaurin response; genomic signatures correlating with response|
|iCare 5||Leukemia||Strekalova||Using social medial to assess care plans and goals with leukemia patients|
|iCare 6||AML||Lamba, Norkin||Anti-CD33 therapy for AML based on CD33 SNPs|
|iCare 7||MDS||Cogle||Defining genomic signatures associating with lenalidomide response in non-del(5q) MDS|
|iCare 8||MM||Murthy||Randomized controlled trial of computer-informed vs. conventional care|
|iCare 9||Relapsed and refractory AML||Cogle||Randomized controlled trial of computer-informed vs. conventional care|
|iCare 10||AML||Cogle, Lamba||Randomized controlled trial of genotype assigned cytarabine dosing|